NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

NCT05132101

CompletedN/A

Sponsor: Pfizer

Conditions: Metastatic Breast Cancer

Interventions: Patients who received Palbociclib as first line therapy in MBC setting

Countries: South Korea

The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period
* Patients who were diagnosed with BC during the index period

Exclusion Criteria:

* Male
* Prescribed with palbociclib during 12-month period preceding the index date

Locations (1)

Seoul, South Korea